Participated · Series A · Jul 2026

Telum Therapeutics, founded in 2019, is developing protein-based antimicrobial therapies using its proprietary APEX platform. Its lead programme targets severe infections caused by Acinetobacter baumannii, specifically hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The company plans to use the Series A proceeds to complete Phase 1 clinical development of the lead candidate and to advance its broader pipeline against both Gram-negative and Gram-positive pathogens. Telum positions its approach as potentially overcoming limitations of existing antibiotic treatments. No revenue, user, or other operating metrics were disclosed in the announcement. The company highlighted support from both public and private Spanish and international investors as part of its financing.

Led · Equity · May 2026

Founded in 2020, Fresh People develops an AI-native platform to support leadership development, performance management, team effectiveness and cultural transformation. Its flagship offering, Booster, is positioned as an AI leadership copilot that integrates into managers' existing tools and has been adopted by over 2,000 managers. The company reports that integrating AI into goal setting has increased individual and team goal achievement by more than 45% and reduced talent attrition by 23%. Notable clients include Acciona, LaLiga and Kave Home. Fresh People combines proven leadership, strategy and change methodologies with AI to translate corporate strategy into day-to-day team actions. With the new funding the company plans to scale Booster and pursue international expansion, centralising its operations through booster.team.

Participated · Seed · May 2026

Dolfin builds an AI-driven platform that automates sales incentive and commission management and integrates with CRM, ERP and HRIS systems to provide deal-level payout visibility and performance tracking. The company was founded in 2023 and is led by CEO Daniel Seror and CPO Antoni Bardina. Dolfin has achieved SOC 2 certification and manages commission architectures for large enterprise clients with combined annual turnover exceeding €851 million. Following its €2.1m Seed raise, the company plans to accelerate engineering, expand commercial go-to-market teams, and pursue market penetration across Europe and the United States. The article did not disclose revenue figures or prior funding rounds.

Led · Seed · Apr 2026

Iteria Biopharma was founded in 2024 and is headquartered in Touro (A Coruña); its leadership team includes co-founders from GalChimia, Julio Castro (Palobiofarma) and CEO Ramon Bosser. The company’s lead asset is ITR-251, a novel molecule targeting metastatic castration-resistant prostate cancer, and it also runs two early research programs aimed at pancreatic, colorectal and lung cancers. Iteria uses unconventional medicinal chemistry approaches to discover candidates for cancers where existing therapies fail. Following the €5 million Series Seed round, the company plans to complete regulatory preclinical work and initiate a Phase 1 trial for ITR-251 in early 2027. The funding will also support identification and preclinical progression of candidates in its two other oncology programs over the next two years. Iteria has previously been supported by founders’ capital and public grants from MICINN and CDTI."}

Participated · Equity · Feb 2026

Pharmacelera deploys its proprietary 3-D Quantum Mechanics and Artificial Intelligence engine, branded QaiM, to search the chemical “exaSpace” of trillions of molecules with high speed and accuracy. The platform can deliver drug candidates up to ten times better and 75,000 times faster than traditional AI-led discovery methods, and is applicable from hit identification through lead optimization. To date the company’s cross-disciplinary team has executed more than 100 discovery projects and secured repeat business from three large pharmaceutical companies as well as numerous biotech clients. Pharmacelera operates from Parc Científic de Barcelona, one of Europe’s key life-science hubs, and maintains a diversified, scalable service model. The firm formed a strategic alliance in 2023 with Silicon Valley “igniter” General Inception, becoming that group’s AI drug-discovery partner and strengthening IP for several GI portfolio companies. Current plans include establishing a permanent U.S. team to deepen relationships with biopharma customers on both coasts and expanding the technical capabilities of the QaiM engine. Although revenue figures were not disclosed, the repeat engagements with big pharma and over a hundred completed projects indicate growing commercial traction.